Outlook Therapeutics, Inc.OTLKNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+19489.2%
5Y CAGR+2176.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+19489.2%/yr
Annual compound
5Y CAGR
+2176.0%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
6106818.9x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 65082963.96% |
| 2024 | 57.88% |
| 2023 | -37.51% |
| 2022 | 8.66% |
| 2021 | 47.89% |
| 2020 | 10.66% |
| 2019 | 28.65% |
| 2018 | -22.28% |
| 2017 | -27.33% |
| 2016 | -15.72% |